Involvement of A
Adenosine
/ analogs & derivatives
Adenosine A3 Receptor Agonists
/ pharmacology
Adenosine A3 Receptor Antagonists
/ pharmacology
Basic Helix-Loop-Helix Transcription Factors
/ metabolism
Brain Neoplasms
/ metabolism
Cell Hypoxia
Cell Line, Tumor
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
/ metabolism
MAP Kinase Signaling System
Neuroblastoma
/ metabolism
Receptor, Adenosine A3
/ metabolism
Vascular Endothelial Growth Factor A
/ metabolism
A3 receptor
Adenosine
Hypoxia-inducible factors
Neuroblastoma
Vascular endothelial growth factor
Journal
Journal of molecular neuroscience : MN
ISSN: 1559-1166
Titre abrégé: J Mol Neurosci
Pays: United States
ID NLM: 9002991
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
08
04
2019
accepted:
22
05
2019
pubmed:
6
6
2019
medline:
22
1
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. The clinical course may range from spontaneous regression towards ganglioneuroblastoma/ganglioneuroma or maturation to a very aggressive form characterized by an extensive hypoxic area. In solid tumors, extracellular microenvironment hypoxia induces the transcription of hypoxia-inducible factors (HIFs) leading to synthesis of pro-angiogenic factor, VEGF; also, it increases extracellular adenosine production from ATP breakdown. To date, the role of this nucleoside in the hypoxic/angiogenic pathway characterizing the core of cancer mass has not been investigated yet. Therefore, the aim of the present study was to analyze the adenosine effect on modulation of the HIF-1α/2α/VEGF pathway mediated through A
Identifiants
pubmed: 31166001
doi: 10.1007/s12031-019-01346-4
pii: 10.1007/s12031-019-01346-4
doi:
Substances chimiques
Adenosine A3 Receptor Agonists
0
Adenosine A3 Receptor Antagonists
0
Basic Helix-Loop-Helix Transcription Factors
0
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
Receptor, Adenosine A3
0
Vascular Endothelial Growth Factor A
0
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
152918-18-8
endothelial PAS domain-containing protein 1
1B37H0967P
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
166-176Références
Br J Pharmacol. 2001 Sep;134(1):116-26
pubmed: 11522603
Br J Pharmacol. 2001 Sep;134(1):132-42
pubmed: 11522605
Cell. 2001 Oct 5;107(1):43-54
pubmed: 11595184
Br J Pharmacol. 2001 Nov;134(6):1215-26
pubmed: 11704641
Pharmacol Rev. 2001 Dec;53(4):527-52
pubmed: 11734617
Mol Pharmacol. 2002 Feb;61(2):415-24
pubmed: 11809867
Ann N Y Acad Sci. 2002 Nov;973:448-53
pubmed: 12485909
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Pharmacol Ther. 2003 Oct;100(1):31-48
pubmed: 14550503
Clin Cancer Res. 2004 Sep 1;10(17):5895-901
pubmed: 15355922
Oncogene. 2004 Dec 16;23(58):9427-31
pubmed: 15543236
FASEB J. 2005 Aug;19(10):1308-10
pubmed: 15941769
Cancer Res. 2005 Aug 15;65(16):7267-75
pubmed: 16103078
Neoplasia. 2005 Oct;7(10):894-903
pubmed: 16242072
Anticancer Res. 2006 Jan-Feb;26(1A):43-7
pubmed: 16475677
Biochem Pharmacol. 2006 Jun 28;72(1):19-31
pubmed: 16682012
J Cell Physiol. 2007 Jun;211(3):826-36
pubmed: 17348028
Cell Death Differ. 2007 Jul;14(7):1315-23
pubmed: 17396131
Mol Pharmacol. 2007 Jul;72(1):162-72
pubmed: 17400763
Neoplasia. 2009 Nov;11(11):1132-45
pubmed: 19881949
Clin Cancer Res. 2009 Dec 1;15(23):7130-6
pubmed: 19903792
Biochem Pharmacol. 2010 May 15;79(10):1483-95
pubmed: 20096265
J Oncol. 2012;2012:782020
pubmed: 21876694
Br J Pharmacol. 1990 Aug;100(4):814-8
pubmed: 2207501
Nat Rev Cancer. 2011 Dec 15;12(1):9-22
pubmed: 22169972
Biochem Biophys Res Commun. 2012 Aug 3;424(3):421-6
pubmed: 22766505
Annu Rev Pathol. 2014;9:47-71
pubmed: 23937437
JACC Cardiovasc Interv. 2014 Jun;7(6):581-91
pubmed: 24835328
J Mol Neurosci. 2014 Nov;54(3):405-13
pubmed: 24874579
Crit Rev Biochem Mol Biol. 2014 Nov-Dec;49(6):473-97
pubmed: 25418535
Eur J Pediatr Surg. 2014 Dec;24(6):450-6
pubmed: 25486413
Tumour Biol. 2015 Jul;36(7):5133-41
pubmed: 25656612
Cell Tissue Res. 2015 Oct;362(1):45-60
pubmed: 25948484
Exp Cell Res. 2015 Dec 10;339(2):407-16
pubmed: 26376118
Genes Cancer. 2016 Jan;7(1-2):47-58
pubmed: 27014421
Pharmacol Ther. 2016 Aug;164:152-69
pubmed: 27139518
Front Pharmacol. 2016 May 31;7:139
pubmed: 27303300
J Mol Neurosci. 2017 Feb;61(2):256-266
pubmed: 27909871
J Cell Biochem. 2017 Aug;118(8):2371-2379
pubmed: 28106278
Expert Rev Anticancer Ther. 2017 Apr;17(4):369-386
pubmed: 28142287
Sci Rep. 2017 Jun 19;7(1):3816
pubmed: 28630416
Cell Tissue Res. 2018 May;372(2):269-275
pubmed: 29032465
Peptides. 2018 Jan;99:20-26
pubmed: 29126993
Neuropeptides. 2018 Jun;69:84-91
pubmed: 29699729
J Immunother Cancer. 2018 Jun 18;6(1):57
pubmed: 29914571
Cancer Lett. 2019 Apr 1;446:112-122
pubmed: 30660649
Pharmacol Rev. 1994 Jun;46(2):143-56
pubmed: 7938164
Biochem Biophys Res Commun. 1997 Mar 17;232(2):317-22
pubmed: 9125172
Cancer Res. 1997 Jul 1;57(13):2602-5
pubmed: 9205063